Jun 2026 (Q2 FY26) — Aug 12, 2026
Sera Prognostics Q2 FY26 — Illinois Medicaid Coverage and Expanded Payer Engagement
Read the full callSera Prognostics (SERA) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Sera Prognostics earnings: last reported Wed, 12 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 0.03 | +76.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -33346.7 | +21476.9 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -9.1 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$2.06 +1.48% · +$0.03
Performance −34.2% 1Y
1Y: $3.13 on 15 Oct 2025 → $2.06. High $3.75 (28 Oct 2025), low $1.59 (13 May 2026).
- Previous close
- $2.03
- 52-week range
- $1.59 – $3.75
- One year
- −38.32%
Overview
- Symbol
- SERA
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Sera Prognostics earnings calls (SERA)
Financials
What the filings say
Net profit, year on year: −14% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | -9 | -9 | -9 | -9 | -9 | -9 | -9 | -10 |
| Operating margin | −30558.6% | −39262.5% | −24342.1% | −54823.5% | −56125.0% | −89540.0% | −66857.1% | −33346.7% |
| Other income | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -8 | -9 | -8 | -8 | -8 | -8 | -8 | -9 |
| EPS ($ per share) | -0.24 | — | -0.20 | -0.16 | -0.16 | — | -0.17 | -0.18 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -131 | -166 | -211 | -247 | -280 | -312 |
| Total liabilities | 12 | 8 | 17 | 25 | 25 | 27 |
| Fixed assets | 1 | 2 | 3 | 2 | 1 | 1 |
| Investments | 0 | 46 | 53 | 45 | 42 | 35 |
| Total assets | 15 | 147 | 116 | 95 | 73 | 102 |
| Line item | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Cash from operations | -17 | -32 | -35 | -27 | -14 | -26 |
| Cash from investing | -0 | -83 | 6 | 0 | 12 | -29 |
| Cash from financing | 9 | 160 | 0 | 1 | 3 | 54 |
| Capital expenditure | -0 | -1 | -1 | -0 | -0 | -1 |
| Free cash flow | -17 | -33 | -35 | -27 | -14 | -26 |
Insider filings
78 filings between Nov 4, 2025 and Oct 12, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$659.2K
52 sales by 10 insiders
17% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 22
- Award — granted as compensation
- 2
- Option exercise — converted options into shares
Also filed: 2 other filings.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Lindgardt Zhenya | — | $290.5K | Sep 10, 2026 |
| Kearney Paul | — | $131.0K | Mar 11, 2026 |
| Aerts Austin | — | $65.8K | Jun 11, 2026 |
| Harrison Robert Gardner | — | $55.8K | Mar 11, 2026 |
| Jackson Benjamin | — | $38.4K | Sep 10, 2026 |
| Boniface John J. | — | $33.8K | Mar 11, 2026 |
| Inglis Tiffany Eul Davis | — | $18.0K | Oct 12, 2026 |
| Anderson Dyaarl Lee Jr. | — | $13.1K | Sep 10, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 12, 2026 | Inglis Tiffany Eul Davis Chief Medical Officer | Sale | 8,024 | $16.3K |
| Sep 10, 2026 | Lindgardt Zhenya Chief Executive Officer | Sale | 7,022 | $14.0K |
| Sep 10, 2026 | Jackson Benjamin General Counsel | Sale | 2,190 | $4.4K |
| Sep 10, 2026 | Anderson Dyaarl Lee Jr. Chief Commercial Officer | Sale | 1,800 | $3.6K |
| Sep 10, 2026 | Inglis Tiffany Eul Davis Chief Medical Officer | Sale | 486 | $972 |
| Sep 8, 2026 | Lindgardt Zhenya Chief Executive Officer | Sale | 20,139 | $40.3K |
| Aug 31, 2026 | Gleason Scott Chief Financial Officer | Award | 117,924 | $0 |
| Jul 10, 2026 | Kamdar Kim P. Director | Award | 3,421 | $0 |
| Jul 10, 2026 | Capone Mark Christopher Director | Award | 1,975 | $0 |
| Jul 10, 2026 | Phillips Joshua Director | Award | 22,426 | $0 |
| Jul 10, 2026 | Capone Mark Christopher Director | Award | 42,404 | $0 |
| Jul 10, 2026 | Kamdar Kim P. Director | Award | 22,426 | $0 |
| Jul 10, 2026 | CRITCHFIELD GREGORY C Director | Award | 22,426 | $0 |
| Jul 10, 2026 | Mirza Mansoor Raza Director | Award | 22,426 | $0 |
| Jul 10, 2026 | Lawrence Sandra AJ Director | Award | 2,276 | $0 |
| Jul 10, 2026 | Barlow Jane F Director | Award | 1,949 | $0 |
| Jul 10, 2026 | Lawrence Sandra AJ Director | Award | 22,426 | $0 |
| Jul 10, 2026 | Barlow Jane F Director | Award | 22,426 | $0 |
| Jul 10, 2026 | Mirza Mansoor Raza Director | Award | 1,771 | $0 |
| Jul 10, 2026 | CRITCHFIELD GREGORY C Director | Award | 1,594 | $0 |
| Jul 10, 2026 | Phillips Joshua Director | Award | 2,260 | $0 |
| Jun 11, 2026 | Jackson Benjamin General Counsel | Sale | 2,179 | $4.4K |
| Jun 11, 2026 | Inglis Tiffany Eul Davis Chief Medical Officer | Sale | 362 | $728 |
| Jun 11, 2026 | Anderson Dyaarl Lee Jr. Chief Commercial Officer | Sale | 4,739 | $9.5K |
| Jun 11, 2026 | Aerts Austin Chief Financial Officer | Sale | 2,037 | $4.1K |
| Jun 11, 2026 | Lindgardt Zhenya Chief Executive Officer | Sale | 6,990 | $14.0K |
| Jun 9, 2026 | Aerts Austin Chief Financial Officer | Sale | 5,440 | $11.3K |
| Jun 9, 2026 | Lindgardt Zhenya Chief Executive Officer | Sale | 20,755 | $43.2K |
| Jun 8, 2026 | Lawrence Sandra AJ Director | Sale 10b5-1 plan | 1,560 | $3.4K |
| May 29, 2026 | Anderson Dyaarl Lee Jr. Chief Commercial Officer | Award | 3,168 | $5.8K |
| May 29, 2026 | Jackson Benjamin General Counsel | Award | 5,000 | $9.2K |
| Mar 12, 2026 | Inglis Tiffany Eul Davis Chief Medical Officer | Award | 17,437 | $0 |
| Mar 12, 2026 | Anderson Dyaarl Lee Jr. Chief Commercial Officer | Award | 12,455 | $0 |
| Mar 12, 2026 | Aerts Austin Chief Financial Officer | Award | 44,215 | $0 |
| Mar 12, 2026 | Lindgardt Zhenya Chief Executive Officer | Award | 154,440 | $0 |
| Mar 12, 2026 | Jackson Benjamin General Counsel | Award | 44,215 | $0 |
| Mar 11, 2026 | Lindgardt Zhenya Chief Executive Officer | Sale | 2,973 | $6.1K |
| Mar 11, 2026 | Aerts Austin Chief Financial Officer | Sale | 1,019 | $2.1K |
| Mar 11, 2026 | Kearney Paul Chief Data Officer | Sale | 1,396 | $2.8K |
| Mar 11, 2026 | Jackson Benjamin General Counsel | Sale | 1,027 | $2.1K |
| Mar 11, 2026 | Harrison Robert Gardner Chief Information Officer | Sale | 716 | $1.5K |
| Mar 11, 2026 | Boniface John J. Chief Scientific Officer | Sale | 1,517 | $3.1K |
| Mar 10, 2026 | Aerts Austin Chief Financial Officer | Sale | 6,069 | $11.5K |
| Mar 10, 2026 | Lindgardt Zhenya Chief Executive Officer | Sale | 22,639 | $43.0K |
| Mar 9, 2026 | Kearney Paul Chief Data Officer | Sale | 2,026 | $4.0K |
| Mar 9, 2026 | Jackson Benjamin General Counsel | Sale | 3,119 | $6.1K |
| Mar 9, 2026 | Harrison Robert Gardner Chief Information Officer | Sale | 3,360 | $6.6K |
| Mar 9, 2026 | Boniface John J. Chief Scientific Officer | Sale | 3,038 | $6.0K |
| Mar 9, 2026 | Aerts Austin Chief Financial Officer | Sale | 674 | $1.3K |
| Mar 6, 2026 | Lawrence Sandra AJ Director | Sale 10b5-1 plan | 1,560 | $3.0K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for SERA PROGNOSTICS, INC.
Free account. Everything above stays public.
Write why you follow SERA PROGNOSTICS, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading